IPM Take
People with drug-resistant epilepsy are often pushed toward an impossible choice: continue living with seizures, or accept the risks of brain surgery. Early data from AMT-260 do not resolve that dilemma. But they suggest a different ambition, one that aims to change the seizure network without removing brain tissue.
That matters because treatment choice in epilepsy is not only about seizure counts. It is about memory, language, work, driving, fear, family life and the parts of a person that surgery may protect or threaten.
Executive Summary
uniQure’s first low-dose cohort in the Phase I/IIa GenTLE study of AMT-260 included six adults with refractory unilateral mesial temporal lobe epilepsy. At the May 2026 data cut-off, three participants had reductions in disabling seizures ranging from 79% to 100% during months four to six. The other three showed heterogeneous outcomes, ranging from a 33% reduction to a 36% increase in disabling seizures. No serious adverse events related to the gene therapy or surgical delivery procedure were reported.
AMT-260 is an investigational AAV9-based gene therapy delivered directly into the hippocampus through MRI-guided convection-enhanced delivery. It is designed to reduce expression of GRIK2, a gene involved in excitatory kainate receptor signalling. A higher-dose cohort is enrolling, with updated results expected in the first half of 2027.
Why it matters
- Patients / advocates: Drug-resistant epilepsy can shrink a life around seizure avoidance. More treatment choices matter, especially where surgery is declined, unsuitable or feared.
- Clinicians: The early signal is mixed and too small to establish efficacy, but it opens a serious question about targeted molecular alternatives to resection.
- Regulators: Gene therapy in epilepsy will require unusually careful long-term safety, durability and functional-outcome evidence.
Epilepsy surgery can be life-changing. It can also be terrifying.
For people with refractory mesial temporal lobe epilepsy, the decision is rarely simple. Removing or ablating seizure-generating tissue may bring seizure freedom, but it can also carry risks to memory, language and identity. Some patients are not eligible. Others decide that the price is too high.
AMT-260 is trying to create another path.
The treatment is delivered directly into the hippocampus, where it uses engineered microRNAs to reduce GRIK2 expression and dampen a receptor pathway thought to contribute to seizure generation. It is not a non-invasive intervention. It still requires neurosurgical delivery. But the ambition is different from resection: change the network without taking tissue away.
The first cohort results need restraint. Three of six patients experienced large reductions in disabling seizures, while the remaining three had variable outcomes, including worsening seizure control. That is not proof of efficacy. It is a preliminary biological signal in a tiny, open-label cohort.
Still, the human relevance is real.
People with uncontrolled epilepsy do not experience seizures as a number on a chart. They experience them as cancelled workdays, restricted driving, injuries, isolation, medication fatigue and the fear that the next seizure will happen in public, alone or at the wrong time.
The future test for AMT-260 is not whether it produces an impressive graph in a conference presentation. It is whether it can deliver sustained seizure reduction without trading one form of disability for another.
